Search

Your search keyword '"de Marinis, F."' showing total 55 results

Search Constraints

Start Over You searched for: Author "de Marinis, F." Remove constraint Author: "de Marinis, F." Topic oncology Remove constraint Topic: oncology
55 results on '"de Marinis, F."'

Search Results

1. Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)

2. Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

3. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines

4. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

5. The Role of Vindesine and Lonidamine in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer: A Phase III Randomized Fonicap Trial

6. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study

7. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study

8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

9. Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics

10. Supportive care in patients with advanced non-small-cell lung cancer

11. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population

12. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

13. Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis

14. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

15. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

16. Surgery for small cell lung cancer: When and how

17. Understanding EGFR heterogeneity in lung cancer

18. EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials

19. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

20. EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer

21. Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial

22. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

23. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

24. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non–Small-Cell Lung Cancer

25. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes

26. Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

27. The Role of Extended Pulmonary Metastasectomy

28. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

29. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

30. Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

31. Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib

32. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

33. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

34. 'Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.'

35. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

36. Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population

37. Outcome of Patients With pN2 'Potentially Resectable' Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy

38. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

39. Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational 'SUN' (Survey on the lUng cancer maNagement) study

40. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study

41. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

42. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

43. Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel

44. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

45. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

46. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

47. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

48. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

49. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

50. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting

Catalog

Books, media, physical & digital resources